Paying users zone. Data is covered by .
Get to Biogen Inc. for $15.99, or
get to whole website for at least 3 months from $49.99.
Statement of Financial Position, Liabilities and Stockholders' Equity
The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.
Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.
Biogen Inc., Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity (quarterly data)
USD $ in thousands
|Jun 30, 2018||Mar 31, 2018||Dec 31, 2017||Sep 30, 2017||Jun 30, 2017||Mar 31, 2017||Dec 31, 2016||Sep 30, 2016||Jun 30, 2016||Mar 31, 2016||Dec 31, 2015||Sep 30, 2015||Jun 30, 2015||Mar 31, 2015||Dec 31, 2014||Sep 30, 2014||Jun 30, 2014||Mar 31, 2014||Dec 31, 2013||Sep 30, 2013||Jun 30, 2013||Mar 31, 2013|
|Current portion of notes payable|
|Accrued expenses and other|
|Notes payable, excluding current portion|
|Deferred tax liability|
|Other long-term liabilities|
|Preferred stock, par value $0.001 per share|
|Common stock, par value $0.0005 per share|
|Additional paid-in capital|
|Accumulated other comprehensive loss|
|Treasury stock, at cost|
|Total Biogen Inc. shareholders' equity|
|Total liabilities and equity|
|Accounts payable||Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).||Biogen Inc.'s accounts payable declined from Q4 2017 to Q1 2018 and from Q1 2018 to Q2 2018.|
|Current liabilities||Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.||Biogen Inc.'s current liabilities declined from Q4 2017 to Q1 2018 but then slightly increased from Q1 2018 to Q2 2018.|
|Non-current liabilities||Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.||Biogen Inc.'s non-current liabilities increased from Q4 2017 to Q1 2018 but then slightly declined from Q1 2018 to Q2 2018.|
|Total liabilities||Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.||Biogen Inc.'s total liabilities increased from Q4 2017 to Q1 2018 but then slightly declined from Q1 2018 to Q2 2018.|
|Total Biogen Inc. shareholders' equity||Total of all Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest).||Biogen Inc.'s total Biogen Inc. shareholders' equity increased from Q4 2017 to Q1 2018 but then declined significantly from Q1 2018 to Q2 2018.|
|Total equity||Total of Stockholders' Equity (deficit) items, net of receivables from officers, directors owners, and affiliates of the entity including portions attributable to both the parent and noncontrolling interests (previously referred to as minority interest), if any. The entity including portions attributable to the parent and noncontrolling interests is sometimes referred to as the economic entity.||Biogen Inc.'s total equity increased from Q4 2017 to Q1 2018 but then declined significantly from Q1 2018 to Q2 2018.|